Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 9/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22434915 | 0.87 | DOT1L (0.49) | PRMT5WDR77DOT1LMETTL3 | |
| SCHEMBL22435083 | 0.87 | DOT1L (0.49) | PRMT5WDR77DOT1LMETTL3 | |
| SCHEMBL23584688 | 0.87 | DOT1L (0.49) | PRMT5WDR77DOT1LMETTL3 | |
| SCHEMBL23584774 | 0.85 | SIRT2 (0.38) | PRMT5WDR77DOT1LSIRT2SIRT1 | |
| SCHEMBL22434971 | 0.85 | SIRT2 (0.41) | PRMT5WDR77DOT1LSIRT2SIRT1 | |
| SCHEMBL22435004 | 0.84 | PRMT5 (0.37) | PRMT5WDR77DOT1LSIRT2SIRT1 | |
| SCHEMBL23584708 | 0.84 | PRMT5 (0.40) | PRMT5WDR77DOT1LMETTL3ADK | |
| SCHEMBL23584551 | 0.83 | DDR1 (0.36) | PRMT5WDR77 | |
| SCHEMBL19343852 | 0.83 | PRMT5 (0.41) | PRMT5WDR77DOT1LMETTL3 | |
| SCHEMBL23584729 | 0.82 | PRMT5 (0.38) | PRMT5WDR77DOT1LMETTL3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 133/4885DOT1L 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.